MedPath

Comparative Study of GangTrainer GT1, Lokomat and Conventional Physiotherapy

Not Applicable
Suspended
Conditions
Stroke, Acute
Interventions
Device: Lokomat
Other: Conventional Physiotherapy
Device: GangTrainer GT1
Registration Number
NCT01146587
Lead Sponsor
Research Department for Neurorehabilitation South Tyrol
Brief Summary

The GangTrainer GT I and the Lokomat have proven their effectiveness on stroke Patients, but a comparison on the same controlled study population has not been made so far. Aim of the study will not only be to establish which device will work better on acute, non ambulatory stroke Patients in terms of regain of gait ability and motor function, but also clinical matters, like the efficacy of the treatment period. As a result of the trial it should be highlighted which kind of therapy has to be suggested for Patients comparable to the study population. A significant better outcome of one device in regard to the other will suggest to use one device more than the other for future treatments.

Detailed Description

A total of 120 Patients will be enroled in the study and divided into 2 treatment and 1 control group. Enroled Patients will all be first supratentorial non ambulatory stroke patients (ischaemic, haemorrhagic or ICH) with a hemiparesis and stroke onset from 3 - 12 weeks.

Theywill undergo either robotic treatment with the Gangtrainer GT1 or the Lokomat in one of the 2 treatment groups for 30 minutes of gross therapy time every workday for a 8 weeks period if they are in the treatment group, or conventional physiokinetherapy for 30 minutes of gross therapy time every workday for a 8 weeks period if they are in the control group.

Primary outcome will be the Functional Ambulation Category (FAC) assessed at enrolment, after 4 weeks after 8 weeks and at 6 months follow up.

Recruitment & Eligibility

Status
SUSPENDED
Sex
All
Target Recruitment
120
Inclusion Criteria
  • First supratentorial stroke (ischaemic, haemorrhagic or ICH) resulting in a hemiparesis
  • Interval from stroke 3 - 12 weeks
  • Non ambulatory (FAC < 3)
  • Free sitting on bedside for 1 minute, both feet on the floor, ev. holding on bedside by hands
  • Barthel Index 25 - 65
Exclusion Criteria
  • Unstable cardiovascular system (in case of doubt, only after approval by a internist)
  • Manifested heart diseases like labile compensated cardiac insufficiency (NYHA III), angina pectoris, myocardial infarction 120 days before study onset, cardiomyopathy, severe cardiac arrhythmia
  • Severe joint misalignment (severe constriction of movement for hip, knee and/or ankle: more than 20° fixed hip and knee extension deficit, or more than 20° fixed plantar flexion of the ankle
  • Severe cognitive dysfunction, which does not allow for comprehension of the aims of this study
  • Severe neurological or orthopaedic diseases (like polio, Parkinson´s disease), which massively affect the mobility
  • Deep vein thrombosis
  • Severe osteoporosis
  • Malignant tumour diseases

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
LokomatLokomatFirst supratentorial non ambulatory stroke patients (ischaemic, haemorrhagic or ICH) with a hemiparesis and stroke onset from 3 - 12 weeks undergo robotic treatment with the Lokomat for 30 minutes of gross therapy time every workday for a 8 weeks period
Conventional PhysiotherapyConventional PhysiotherapyFirst supratentorial non ambulatory stroke patients (ischaemic, haemorrhagic or ICH) with a hemiparesis and stroke onset from 3 - 12 weeks undergo a conventional physiokinetherapeutic treatment session for 30 minutes of gross therapy time every workday for a 8 weeks period
GangTrainer GT1GangTrainer GT1First supratentorial non ambulatory stroke patients (ischaemic, haemorrhagic or ICH) with a hemiparesis and stroke onset from 3 - 12 weeks undergo robotic treatment with the Gangtrainer GT1 for 30 minutes of gross therapy time every workday for a 8 weeks period
Primary Outcome Measures
NameTimeMethod
Functional Ambulation Category (FAC)after 8 weeks
Secondary Outcome Measures
NameTimeMethod
Medical Research Council (MRC)after 24 weeks
Modified Ashworth Scale (mAS)after 24 weeks
10 metres Walking Testafter 24 weeks
6 Minutes Walking Test on the Floorafter 24 weeks
6 Minutes Walking Test on the Treadmill with Body Weight Supportafter 24 weeks
modified emory Functional Ambulation Profile (meFAP)after 24 weeks
Functional Ambulation Category (FAC)after 24 weeks
Barthel Index (BI)after 24 weeks
EuroQol 5 Dimensions (EQ-5D)after 24 weeks
Rivermead Mobility Index (RMI)after 24 weeks
Rivermead Visual Gait Assessment (RVGA)after 24 weeks

Trial Locations

Locations (7)

Hochzirl Hospital

🇦🇹

Hochzirl, Tirol, Austria

Krankenhaus Bozen

🇮🇹

Bozen, Südtirol, Italy

Krankenhaus Meran

🇮🇹

Meran, Südtirol, Italy

Claudiana Landesfachhochschule

🇮🇹

Bozen, Südtirol, Italy

Privatklinik Villa Melitta

🇮🇹

Bozen, Südtirol, Italy

Krankenhaus Brixen

🇮🇹

Brixen, Südtirol, Italy

Krankenhaus Bruneck

🇮🇹

Bruneck, Südtirol, Italy

© Copyright 2025. All Rights Reserved by MedPath